Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPai, Sara I.
dc.contributor.authorCohen, Ezra E. W.
dc.contributor.authorLin, Derrick
dc.contributor.authorFountzilas, George
dc.contributor.authorKim, Edward S.
dc.contributor.authorMehlhorn, Holger
dc.contributor.authorBasté Rotllan, Neus
dc.date.accessioned2021-04-19T13:34:55Z
dc.date.available2021-04-19T13:34:55Z
dc.date.issued2019-12-26
dc.identifier.citationPai SI, Cohen EEW, Lin D, Fountzilas G, Kim ES, Mehlhorn H, et al. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Transl Med. 2019 Dec 26;17(1):429.
dc.identifier.issn1479-5876
dc.identifier.urihttp://hdl.handle.net/11351/5875
dc.descriptionBiomarcador; Carcinoma de cèl·lules escamoses de cap i coll; PD-L1
dc.description.sponsorshipThis study was sponsored by AstraZeneca. The protocol for this study was developed by the sponsor (AstraZeneca) and advisors. Data were collected collaboratively by the sponsor and clinical investigators. Statisticians employed by the sponsor analyzed the data. All authors participated in the preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofseriesJournal of Translational Medicine;17(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPrognosi
dc.subjectCap - Càncer
dc.subjectColl - Càncer
dc.subject.meshSquamous Cell Carcinoma of Head and Neck
dc.subject.meshPrognosis
dc.titleSUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s12967-019-02182-1
dc.subject.decscarcinoma de células escamosas de cabeza y cuello
dc.subject.decspronóstico
dc.relation.publishversionhttps://translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-02182-1
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Pai SI] Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, GRJ 9 904G, Boston, MA 02114, USA. [Cohen EEW] UC San Diego Health System, Moores Cancer Center, La Jolla, CA, USA. [Lin D] Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, GRJ 9 904G, Boston, MA 02114, USA. Massachusetts Eye and Ear, Boston, MA, USA. [Fountzilas G] Aristotle University of Thessaloniki, Thessaloniki, Greece. [Kim ES] Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. [Mehlhorn H] Universitaet sklinikum Leipzig, Klinik und Poliklinik fur HNO-Heilkunde, Leipzig, Germany. [Baste N] Servei d’Oncologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid31878938
dc.identifier.wos000513524800002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple